Place of birth

iTeos Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates

Retrieved on: 
Mercredi, mars 6, 2024

WATERTOWN, Mass. and GOSSELIES, Belgium, March 06, 2024 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients, today reported financial results for the fourth quarter and full year ended December 31, 2023 and provided a business update.

Key Points: 
  • and GOSSELIES, Belgium, March 06, 2024 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients, today reported financial results for the fourth quarter and full year ended December 31, 2023 and provided a business update.
  • “With the recent developments in the TIGIT field, we believe belrestotug is in an advantageous position and are excited for its future prospects.
  • We look forward to sharing updates from our Phase 2 trials focused on 1L NSCLC and 1L HNSCC in 2024.
  • On December 7, 2023, iTeos announced the appointment of David K. Lee to the Company’s Board of Directors.

LactaLogics Closes $92 Million for Facility, Expanding Access to Human Milk

Retrieved on: 
Vendredi, mars 8, 2024

PORT ST. LUCIE, Fla., March 8, 2024 /PRNewswire-PRWeb/ -- LactaLogics, a pioneer in human milk-based nutrition, is announcing its successful closure of over $92 million in financing. This milestone will enable the company to complete its state-of-the-art facility for the production of human milk-based fortifiers and standardized donor milk.

Key Points: 
  • PORT ST. LUCIE, Fla., March 8, 2024 /PRNewswire-PRWeb/ -- LactaLogics, a pioneer in human milk-based nutrition, is announcing its successful closure of over $92 million in financing.
  • This milestone will enable the company to complete its state-of-the-art facility for the production of human milk-based fortifiers and standardized donor milk.
  • - Glenn Snow, CEO and co-founder
    The benefits of human milk for infant development are extensively documented in scientific literature.
  • Through innovative large-scale manufacturing, leveraging their proprietary Gentle-UHT™ processing technology, LactaLogics is expanding access to human milk, ensuring a reliable supply of critical nutrition.

Hidden women of history: Saint Perpetua, a young mother put to death in a Roman amphitheatre

Retrieved on: 
Mercredi, février 7, 2024

In 203 CE, a young, African Christian woman named Vibia Perpetua was executed in a brutal fashion.

Key Points: 
  • In 203 CE, a young, African Christian woman named Vibia Perpetua was executed in a brutal fashion.
  • This horrific scene formed part of the celebrations for the birthday of Caesar Geta, the son of the emperor Septimius Severus.
  • The Roman imperial state did not engage in a systematic, empire-wide persecution of Christians in the early third century.

Still breastfeeding when jailed

  • The narrator states these chapters are the work of Perpetua herself “just as she wrote with her own hand and according to her own perception”.
  • The narrator tells us Perpetua came from a respectable family, was educated and in her early twenties when she died.
  • She was still breastfeeding when jailed.
  • Perpetua’s account begins after she and four other Christians, including the enslaved woman Felicitas, have been arrested by Roman authorities.

‘I was tormented by concern for my baby’

  • “I was tormented by concern for my baby”, she writes of her initial incarceration.
  • She is later allowed to suckle her baby, who had been “weak with hunger” without his mother.
  • After Perpetua and her fellow Christians are sentenced to die in the amphitheatre, she is filled with anguish for her child.

In her own words?

  • Perpetua’s story was known to the African Christian intellectual Tertullian, who mentions her martyrdom in his book On the Soul, written five to ten years after her execution.
  • This proves there was a Perpetua, but not that she was the author of these eight chapters.
  • One important argument against such scepticism is the style of Perpetua’s Latin is quite different from the narrator’s.

Children and holy women


The degree of Perpetua’s concern for and interaction with her child is unusual in accounts of Christian holy women. For example, Melania the Younger, who lived in Rome in the fifth century CE, desired to become an ascetic, which meant she needed to renounce all worldly ties, including her family.

  • When Melania’s two children died young, she interpreted this as God’s endorsement of her desire to reject the conventions of Roman marriage and motherhood.
  • Some Christian women rejected motherhood in favour of devoting themselves exclusively to their faith, either through martyrdom or asceticism, while others engaged in child-rearing for the good of the larger community.
  • Read more:
    Hidden women of history: Olympias, who took on an emperor, dodged a second marriage and fought for her faith

Family ties

  • In many early Christian texts, it is a woman’s husband who poses an obstacle to the holy path she has chosen, but in Perpetua’s narrative, it is her father.
  • I gave thanks to the lord because my father was not present, and I was refreshed by his absence.
  • Visiting Perpetua in prison, he kisses her hands and prostrates himself before her feet, begging her to consider her family’s reputation.
  • This is a typical theme of Christian hagiography, since the hero or heroine’s journey represents a rejection of the futures their family had planned for them.
  • And yet the attention Perpetua’s account gives to her family and their suffering is unusual.

Perpetua’s legacy

  • While Perpetua does not even mention Felicitas in her first-person narrative, the women became inseparable in the Christian tradition.
  • The writings of Saint Augustine show the Passion was read out in North African churches on their feast day (March 7).
  • This allows us to understand the motivations and sufferings of an African woman who lived almost 2,000 years ago.


Caillan Davenport has received funding from the Australian Research Council and the Alexander von Humboldt Foundation. Meaghan McEvoy has received funding from the British Academy, Dumbarton Oaks and the Alexander von Humboldt Foundation.

MemorialCare Launches New Women's Heart Center and Recruits Nissi Suppogu, M.D. as Medical Director - Creating Sub-Specialized Women's Heart Health Center in Community

Retrieved on: 
Jeudi, février 1, 2024

FOUNTAIN VALLEY, Calif., Feb. 1, 2024 /PRNewswire/ -- MemorialCare, a prominent nonprofit Southern California integrated health system, has announced the launch of the Women's Heart Center at the MemorialCare Heart & Vascular Institute – a specialized center dedicated solely to expertise in education, prevention, early diagnosis, and timely management of women-specific cardiac presentations across their lifespan. The Women's Heart Center's first site will be in conjunction with Long Beach Medical Center and MemorialCare Medical Group, with future plans to expand to additional MemorialCare sites in Orange County.

Key Points: 
  • The Women's Heart Center's first site will be in conjunction with Long Beach Medical Center and MemorialCare Medical Group , with future plans to expand to additional MemorialCare sites in Orange County.
  • To lead a dynamic and distinctive program such as this, MemorialCare has recruited and appointed Nissi Suppogu, M.D.
  • as the medical director of the Women's Heart Center.
  • Dr. Suppogu is fellowship trained, meaning she has two years of additional sub-specialty training and education in women's heart health.

Comanche Biopharma Closes Oversubscribed $75 Million Series B Financing to Advance Mission to Develop and Make Globally Available the First Treatment Targeting a Root Cause of Preeclampsia

Retrieved on: 
Mercredi, janvier 17, 2024

Preeclampsia is a prevalent and serious pregnancy complication that affects approximately 10 million women globally each year.

Key Points: 
  • Preeclampsia is a prevalent and serious pregnancy complication that affects approximately 10 million women globally each year.
  • It can lead to serious complications for both the mother and the baby, including multi-organ damage, seizures, and premature birth.
  • Currently, delivery of the baby, often very prematurely, is the only available option for stopping the progression of preeclampsia.
  • Scott Johnson, M.D., Chief Executive Officer at Comanche Biopharma, commented, “We are thrilled to have the support and validation of this top-tier investor syndicate.

NGM Bio Announces New Clinical Data from Ongoing Trial of NGM707 in Advanced Solid Tumors and Outlines Evolved Strategy for Aldafermin and NGM120 to Focus on Rare Conditions with Significant Unmet Need

Retrieved on: 
Mardi, janvier 9, 2024

NGM Bio also outlined its strategy to evolve clinical development of its product candidates aldafermin and NGM120 to focus on rare conditions characterized by significant unmet need.

Key Points: 
  • NGM Bio also outlined its strategy to evolve clinical development of its product candidates aldafermin and NGM120 to focus on rare conditions characterized by significant unmet need.
  • Recent landmark genetic research confirmed the link between this rare, devastating condition experienced during pregnancy to higher levels of GDF15.
  • Given our deep expertise in GDF15 biology, we believe we are well positioned to potentially pursue this indication for NGM120.
  • NGM Bio previously reported data from a randomized, double-blind, placebo-controlled Phase 2 study of aldafermin for the treatment of PSC.

Chiesi Group and Oak Hill Bio announce License and Development Agreement to develop, manufacture, and commercialize OHB-607, a potentially transformative neonatal therapy

Retrieved on: 
Mardi, janvier 9, 2024

OHB-607 is a recombinant version of insulin-like growth factor-1 (IGF-1), a key driver of fetal growth and development, and its binding protein, IGFBP-3.

Key Points: 
  • OHB-607 is a recombinant version of insulin-like growth factor-1 (IGF-1), a key driver of fetal growth and development, and its binding protein, IGFBP-3.
  • For the developing fetus, mothers are the primary source of IGF-1.
  • Clinical studies conducted to date have demonstrated OHB-607’s potential to significantly reduce the risk of severe BPD1.
  • Their deep expertise in neonatology will help to rapidly advance this promising therapy to patients.”
    Guggenheim Securities LLC acted as exclusive financial advisor to Oak Hill Bio and Goodwin Procter LLP served as its legal advisor.

NEW LUCKY F*CK AD PROVES EVERYONE NEEDS A GOOD F*CK

Retrieved on: 
Jeudi, janvier 11, 2024

AUSTIN, Texas, Jan. 11, 2024 /PRNewswire/ -- Admit it, life is f*cking hard, and everyone needs a good f*ck to get through the day.

Key Points: 
  • AUSTIN, Texas, Jan. 11, 2024 /PRNewswire/ -- Admit it, life is f*cking hard, and everyone needs a good f*ck to get through the day.
  • Lucky F*ck better-for-you energy drink debuted its new video ad campaign today that doesn't mince words when it comes to what we crave as primal beings.
  • On the heels of its $4 million investment announcement with Imaginary Ventures, Lucky F*ck once again demonstrates its aggressive ascension in the beverage category.
  • The name Lucky F*ck comes from a bracelet gifted to Richard by his son for Christmas to celebrate the life he's lived.

iTeos Announces 2024 Strategic Priorities and Anticipated Milestones

Retrieved on: 
Lundi, janvier 8, 2024

WATERTOWN, Mass. and GOSSELIES, Belgium, Jan. 08, 2024 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients, today outlined business updates and strategic priorities for 2024.

Key Points: 
  • and GOSSELIES, Belgium, Jan. 08, 2024 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients, today outlined business updates and strategic priorities for 2024.
  • “Over the past twelve months, the TIGIT competitive landscape has substantially evolved, further positioning iTeos and GSK as a potential leader with our high-quality TIGIT:PD-1 doublet, belrestotug + dostarlimab.
  • The Company plans to integrate IO-001 biomarker knowledge into the development strategy of future inupadenant clinical trials.
  • The Company continues to expect its cash balance to provide runway through 2026, which includes the initiation of multiple Phase 3 registrational trials assessing the belrestotug + dostarlimab doublet.

Gynesonics Announces New Category 1 CPT Code for its Sonata Transcervical RF Ablation Procedure Used to Treat Uterine Fibroids

Retrieved on: 
Mardi, janvier 2, 2024

The new code is effective January 1, 2024, and is defined as CPT 58580 Transcervical ablation of uterine fibroid(s), including intraoperative ultrasound guidance and monitoring, radiofrequency.

Key Points: 
  • The new code is effective January 1, 2024, and is defined as CPT 58580 Transcervical ablation of uterine fibroid(s), including intraoperative ultrasound guidance and monitoring, radiofrequency.
  • Commenting on the new CPT code, Skip Baldino, President and Chief Executive Officer of Gynesonics said, “We are very pleased that the AMA has established a new Category I code that applies to our Sonata® Procedure for the treatment of uterine fibroids.
  • The code is a critical milestone for the broader adoption of the technology to treat uterine fibroids in the United States.
  • Fibroids are treated from inside the uterus, so the Sonata Procedure requires no incisions, no tissue is surgically removed, and the uterus is preserved.